Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy

Epilepsy and Behavior

Volumn 22, Issue 2, 2011, Pages 370-375

  Helmers, Sandra L ^a   Duh, Mei Sheng ^b   Guérin, Annie ^b   Sarda, Sujata P ^b   Samuelson, Thomas M ^b   Bunker, Mark T ^c   Olin, Bryan D ^c   Jackson, Stanley D ^a   Faught, Edward ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ANALYSIS GROUP   (United States)

^c Cyberonics Inc   (Italy)

Author keywords

Complex partial seizures; Cost savings; Costs; Drug resistant epilepsy; Refractory epilepsy; Resource utilization; Vagus nerve stimulation

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; IMMUNOMODULATING AGENT; LITHIUM; NEUROLEPTIC AGENT;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DEATH; DEVICE REMOVAL; DRUG COST; DRUG RESISTANT EPILEPSY; EPILEPSY; EPILEPTIC STATE; FEMALE; GRAND MAL EPILEPSY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IMPLANTABLE NEUROSTIMULATOR; IMPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MONOTHERAPY; SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

ADOLESCENT; ADULT; COHORT STUDIES; COSTS AND COST ANALYSIS; EPILEPSY; FEMALE; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VAGUS NERVE STIMULATION; YOUNG ADULT;

EID: 80053383749     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.07.020     Document Type: Article

References (33)

1. Hauser W.A., Hesdorffer D.H. Epilepsy: frequency, causes and consequences 1990, 1-51. Demos Press, New York.
2. Begley C.E., Annegers J.F., Lairson D.R., et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994, 35:1230-1243.
3. Begley C.E., Famulari M., Annegers J.F., et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000, 42:342-351.
4. Halpern M., Rentz A., Murray M. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology 2000, 19:87-99.
5. Murray M.I., Halpern M.T., Leppik I.E. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996, 23:139-148.
6. Cockerell O.C., Hart Y.M., Sander J.W., et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994, 18:249-260.
7. Gessner U., Sagmeister M., Horisberger B. The costs of epilepsy in Switzerland. Int J Health Sci 1993, 4:121-128.
8. Berto P., Tinuper P., Viaggi S. Cost-of-illness of epilepsy in Italy: data from a multicentre observational study (Episcreen). Pharmacoeconomics 2000, 17:197-208.
9. De Zelicourt M., Buteau L., Fagnani F., et al. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Seizure 2000, 9:88-95.
10. Hamer H.M., Spottke A., Aletsee C., et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006, 47:2165-2172.
11. Garcia-Contreras F., Constantino-Casas P., Castro-Rios A., et al. Direct medical costs for partial refractory epilepsy in Mexico. Arch Med Res 2006, 37:376-383.
12. Begley C.E., Annegers J.F., Lairson D.R., Reynolds T.F., Huser W.A. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994, 35:1230-1243.
13. Meador K.J. Cognitive outcomes and predictive factors in epilepsy. Neurology 2002, 58(8, Suppl. 5):S21-S26.
14. Epilepsy Foundation Depression and mood disorders. Epilepsy Behav 2002, 3:2-3.
15. Van Ness P.C. Therapy for the epilepsies. Arch Neurol 2002, 59:732-735.
16. Griffiths R.I., Schrammel P.N., Morris G.L., Wills S.H., Labiner D.M., Strauss M.J. Payer costs of patients diagnosed with epilepsy. Epilepsia 1999, 40:351-358.
17. Lhatoo S.D., Langan Y., Sander J.W. Sudden unexpected death in epilepsy. Postgrad Med J 1999, 75:706-709.
18. Annegers J.F., Coan S.P., Hauser W.A., Leestma J., Duffell W., Tarver B. Epilepsy, vagal nerve stimulation by the NCP system, mortality, and sudden, unexpected, unexplained death. Epilepsia 1998, 39:206-212.
19. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342(5):314-319.
20. Wiebe S., Blume W.T., Girvin J.P., Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001, 345:311-318.
21. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 1995, 45:224-230. The Vagus Nerve Stimulation Study Group.
22. Handforth A., DeGiorgio C.M., Schachter S.C., et al. Vagus nerve stimulation therapy for partial-onset seizures. Neurology 1998, 51:48-55.
23. Hallböök T., Lundgren J., Stjernqvist K., Blennow G., Strömblad L.G., Rosén I. Vagus nerve stimulation in 15 children with therapy resistant epilepsy: its impact on cognition, quality of life, behaviour and mood. Seizure 2005, 14:504-513.
24. De Herdt V., Boon P., Ceulemans B., et al. Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study. Eur J Paediatr Neurol 2007, 11:261-269.
25. Kuba R., Brázdil M., Kalina M., et al. Vagus nerve stimulation: longitudinal follow-up of patients treated for 5years. Seizure 2009, 18:269-274.
26. Ben-Menachem E., Hellström K., Verstappen D. Analysis of direct hospital costs before and 18months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology 2002, 59(Suppl. 4):S44-S47.
27. Boon P., D'Havé M., Van Walleghem P., et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 2002, 43:96-102.
28. Bernstein A.L., Barkan H., Hess T. Vagus nerve stimulation therapy for pharmacoresistant epilepsy: effect on health care utilization. Epilepsy Behav 2007, 10:134-137.
29. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
30. Kuhn L., Davidson L.L., Durkin M.S. Use of Poisson regression and time series analysis for detecting changes over time in rates of child injury following a prevention program. Am J Epidemiol 1994, 140:944-955.
31. Schuele S.U., Luders H.O. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008, 7:514-524.
32. VNS therapy system - P 970003s050 Available at:, Accessed on: July 6, 2011. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078532.htm.
33. Shirk C. Medicaid and mental health services. National Health Policy Forum 2008, Background Paper No. 66.